Destiny Pharma PLC (LON:DEST) said it has appointed of Professor Mark Wilcox to its Scientific Advisory Board.
The drug developer noted that Wilcox is a consultant microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospitals, he is also the lead on Clostridium difficile (C. difficile) infection for Public Health England.
In addition, Wilcox has advisory roles to UK SAGE (COVID-19), NHS England's Infection Prevention & Control national team and Public Health England’s Rapid Review and is a member of the NHS Antimicrobial Resistance Programme Board.
In a statement, Destiny's chief scientific officer, Dr Bill Love, said: “We are pleased to welcome Professor Wilcox, who is a recognised leader in UK and NHS infection prevention and control and a globally renowned expert in C. difficile infection.
“His knowledge compliments the existing expertise on our scientific advisory board as we plan for phase III trials for our recently acquired asset, NTCD-M3, which is targeting the prevention of C. difficile infection recurrence.”
Love added thst Wilcox will also bring an “expert understanding” of MRSA and COVID-19 infections which he said would provide valuable insight for the company’s preventative products in development - namely XF-73 and SPOR-COV.
In a separate announcement, Destiny said its chief executive, Neil Clark, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually at 3.00pm on Tuesday, February 2, 2020.
The title is: Investing in Infectious Disease - How Will the Covid Pandemic Transform the Development, Commercialisation, And Partnering Landscape?